Precision BioSciences (DTIL) shares were up nearly 27% in recent trading Friday, a day after its partner iEcure reported positive data on its in vivo gene insertion program and upgrade Friday from BMO Capital.
BMO Capital upgraded the company's stock to outperform from market perform, with a $34 price target.
iEcure reported positive data from the phase 1/2 study in the first patient treated with ECUR-506 for neonatal onset OTC deficiency, a hereditary metabolic disorder.
The treatment was well-tolerated overall, with only asymptomatic transaminitis noted at four weeks, which was managed with immunosuppressive therapy and resolved within another four weeks, it added.
Price: 5.70, Change: +1.20, Percent Change: +26.67
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.